Sarah A Holstein

Jan 16, 2025 | ascpt.onlinelibrary.wiley.com | Sarah A Holstein

As the sales of opioids rapidly increased in the United States at the turn of this century, so too did admissions for opioid abuse treatment and deaths due to opioid overdose.1 The resulting opioid epidemic has devastated innumerable lives as well as strained an already struggling healthcare system.

Jul 7, 2024 | nature.com | Ajai Chari |Jonathan Kaufman |Jacob P. Laubach |Brandi N. Reeves |Luciano Costa |Sarah A Holstein | +4 more

AbstractThe randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM). We present final post hoc analyses (median follow-up, 49.6 months) of clinically relevant subgroups, including patients with high-risk cytogenetic abnormalities (HRCAs) per revised definition (del[17p], t[4;14], t[14;16], t[14;20], and/or gain/amp[1q21]).

Apr 21, 2024 | nature.com | Natalie S. Callander |Jonathan Kaufman |Jacob P. Laubach |Timothy Schmidt |Brandi N. Reeves |Binod Dhakal | +8 more

AbstractIn the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/dexamethasone (D-RVd) improved outcomes for transplant-eligible NDMM. Here, we present a post hoc analysis of patients with high-risk cytogenetic abnormalities (HRCAs; del[17p], t[4;14], t[14;16], t[14;20], or gain/amp[1q21]).